12,372 trials
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 6.1…
Endogenous Cushing's Syndrome
Primary: Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic…
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Overall Survival Rate at 5 Years — 71; 72 Percentage of participants
Covid19
Primary: Number of Participants Who Had Progression of COVID-19 Through Day 29 — 6; 30 Participants — p=<0.001
Otomycosis
Primary: Percentage of Subjects With Therapeutic Cure — 14; 11; 53; 53 Participants
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL)
Primary: Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period) — 81.4; 83.9; 88.3; 87.1…
COVID-19 · Coronavirus · SARS-CoV-2
Primary: COVID-19 7-point Ordinal Clinical Progression Outcomes Scale Score — 150; 144; 157; 167 Participants
Major Depressive Disorder
Primary: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Scores — 11; 12 score on a scale — p=0.58
Secondarily Infected Traumatic Skin Lesions
Primary: Proportion of Subjects in Each Treatment Group With Clinical Cure (Defined as a Skin Infection Rating Scale (SIRS) Score of 0 for All Signs and Symptoms) — 145; 169; 124…
HIV
Primary: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period — .64; .23; .36; .77…
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 — 108; 8 Participants — p=<0.0001
Psoriasis
Primary: Static Physician's Global Assessment (sPGA) 0/1 Response as a Number of Participants With a sPGA Score of 0 or 1 at Week 16 — 52; 0; 4 Participants
Psoriasis
Primary: The Percentage of Participants With sPGA Response of 0 or 1 — 55.6; 6.8 Percentage of participants — p=<0.0001
Cytomegalovirus Infection
Primary: Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant — 2.8; 18.9…